ArticleDiscover oncology2026
Bioinformatic analysis and cellular functional assays uncover the role of NXPH4 in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTo investigate the relationship between NXPH4 expression and prognosis in breast cancer (BRCA) and to elucidate its potential functional role.
methodsNXPH4 expression data in breast tumor and normal tissues were collected from the TCGA, GTEx, and GEO databases. Its expression localization was assessed using single-cell sequencing and spatial transcriptomics. The impact of NXPH4 on breast cancer cell proliferation and apoptosis was validated experimentally via CCK-8, EdU assays, and Western Blot. Kaplan-Meier analysis was used to evaluate the correlation between NXPH4 expression and Overall Survival (OS), Disease-Specific Survival (DSS), Progression-Free Interval (PFI), and Disease-Free Interval (DFI) in the TCGA cohort. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were performed to explore the biological pathways associated with NXPH4-related differentially expressed genes. The associations of NXPH4 with immune cell infiltration and immune-related genes were examined across multiple datasets. The UALCAN and MethSurv databases were utilized to assess NXPH4 promoter methylation levels and the prognostic significance of specific hypermethylated sites. Drug sensitivity in BRCA patients was predicted using the GDSC1 and GDSC2 databases.
resultNXPH4 expression was significantly upregulated in breast cancer tissues and was primarily localized to malignant cells. In vitro experiments demonstrated that inhibiting NXPH4 affected breast cancer cell proliferation and apoptosis levels. Patients with high NXPH4 expression had a significantly shorter overall survival. The methylation level of the NXPH4 promoter was higher in tumor tissues compared to normal tissues, and methylation at specific sites was closely associated with patient prognosis. NXPH4 expression was correlated with cell cycle regulation, invasion processes, immune cell infiltration, and immune-related gene expression. High NXPH4 expression was associated with higher IC50 values for most chemotherapeutic drugs, suggesting relative chemoresistance, whereas drugs with lower IC50 values showed potentially better inhibitory effects.
conclusionNXPH4 is highly expressed in breast cancer and is associated with poor prognosis. It may influence disease progression by regulating cell proliferation, immune infiltration, and other processes, indicating its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.